clinical trial · NCT07234942
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
Alzheimer's DiseaseRO7812653Placebo
brief summary
This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.
started
Jan 27, 2026
primary completion
Apr 19, 2028
completion
Mar 5, 2030
last updated
Jun 30, 2026
official title
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 Following Intrathecal Administration in Participants With Early Symptomatic Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol